133 related articles for article (PubMed ID: 38591703)
1. A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
Qian H; Chi C; Tricard T; Zhu Y; Dong L; Wang Y; Sha J; Wang J; Ma Z; Wang Y; Liu J; Dong B; Pan J; Xue W
J Urol; 2024 May; 211(5):648-655. PubMed ID: 38591703
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
[TBL] [Abstract][Full Text] [Related]
3. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
Eastham JA; Heller G; Halabi S; Monk JP; Beltran H; Gleave M; Evans CP; Clinton SK; Szmulewitz RZ; Coleman J; Hillman DW; Watt CR; George S; Sanda MG; Hahn OM; Taplin ME; Parsons JK; Mohler JL; Small EJ; Morris MJ
J Clin Oncol; 2020 Sep; 38(26):3042-3050. PubMed ID: 32706639
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis.
Chi C; Fan L; Dong B; Zhu Y; Xin Z; Pan J; Xue W
Clin Genitourin Cancer; 2021 Aug; 19(4):e223-e234. PubMed ID: 33824096
[TBL] [Abstract][Full Text] [Related]
6. The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
Wang Y; Wu G; Fan L; Pan J; Gong Y; Fei X; Du X; Zhu Y; Xue W
Prostate; 2021 Jun; 81(8):463-468. PubMed ID: 33822399
[TBL] [Abstract][Full Text] [Related]
7. Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.
Narita S; Nara T; Kanda S; Numakura K; Saito M; Inoue T; Satoh S; Nanjo H; Tsuchiya N; Mitsuzuka K; Koie T; Kawamura S; Ohyama C; Tochigi T; Arai Y; Habuchi T
Clin Genitourin Cancer; 2019 Feb; 17(1):e113-e122. PubMed ID: 30391137
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer.
Sasaki T; Nishikawa K; Kato M; Masui S; Yoshio Y; Sugimura Y; Inoue T
Med Sci (Basel); 2021 Apr; 9(2):. PubMed ID: 33918590
[TBL] [Abstract][Full Text] [Related]
9. Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial.
Sumiyoshi T; Wang X; Warner EW; Sboner A; Annala M; Sigouros M; Beja K; Mizuno K; Ku S; Fazli L; Eastham J; Taplin ME; Simko J; Halabi S; Morris MJ; Gleave ME; Wyatt AW; Beltran H
J Natl Cancer Inst; 2024 Jan; 116(1):115-126. PubMed ID: 37676819
[TBL] [Abstract][Full Text] [Related]
10. Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits.
Zhu Y; Fan L; Zhu H; Gong Y; Chi C; Wang Y; Pan J; Dong B; Xue W
Front Oncol; 2023; 13():963411. PubMed ID: 37265786
[TBL] [Abstract][Full Text] [Related]
11. Head-to-head comparisons of [
Ke ZB; Chen SM; Chen JY; Chen SH; You Q; Sun JB; Xue YT; Sun XL; Wu XH; Zheng QS; Wei Y; Xue XY; Xu N
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1240-1251. PubMed ID: 36416906
[TBL] [Abstract][Full Text] [Related]
12. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
13. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
14. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
15. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis.
Liu W; Yao Y; Liu X; Liu Y; Zhang GM
Asian J Androl; 2021; 23(4):429-436. PubMed ID: 33586699
[TBL] [Abstract][Full Text] [Related]
17. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
[TBL] [Abstract][Full Text] [Related]
18. Comparison of neoadjuvant chemohormonal therapy vs. extended pelvic lymph-node dissection in high-risk prostate cancer treated with robot-assisted radical prostatectomy.
Oishi T; Hatakeyama S; Tabata R; Fujimori D; Fukuda M; Shinozaki T; Ishii N; Iwamura H; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Sato S; Ohyama C
Sci Rep; 2023 Mar; 13(1):3436. PubMed ID: 36859718
[TBL] [Abstract][Full Text] [Related]
19. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract][Full Text] [Related]
20. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
